Program
ibutamoren
Also written as “LUM-201” and “MK0677”.
Its studies are mostly in Dwarfism, Pituitary · Obesity · Hip Fractures · Alzheimer Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lumos Pharma | 75 open or running | phase 3since Apr 21, 2025 | Oct 26, 2020 | Dec 2027phase 3 · NCT06948214 |
| Merck | 20 open or running | phase 2since Dec 15, 2003 | Dec 15, 2003 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 15, 2003First study: phase 2 study in Alzheimer DiseaseNew to MerckMerck · NCT00074529 · 512 enrolled
- Aug 5, 2005Phase 2 study in Hip FracturesMerck · NCT00128115 · 83 enrolled · Germany, Norway, Spain and more
- Oct 26, 2020Lumos Pharma's first study: phase 2 study in Dwarfism, PituitaryNew to Lumos PharmaLumos Pharma · NCT04614337 · 104 enrolled · United States, Australia, Israel and more
- Mar 17, 2021Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT04806854 · 24 enrolled · Chile
- Feb 10, 2022Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05250063 · 15 enrolled · United States, Poland
- Mar 19, 2023Phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05796440 · 60 planned · United States, Australia
- Apr 21, 2025Phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT06948214 · 150 planned · United States, Argentina, Australia and more
- Aug 5, 2025Phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT07129759 · 150 planned
- Jul 9, 2026Phase 2 study in ObesityLumos Pharma · NCT07754045 · 202 planned
Ahead
- Dec 2027Primary completion: phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT06948214
- Feb 15, 2028Primary completion: phase 2 study in ObesityLumos Pharma · NCT07754045
- Mar 2028Primary completion: phase 2 study in Dwarfism, PituitaryLumos Pharma · NCT05796440
- Feb 2030Primary completion: phase 3 study in Dwarfism, PituitaryLumos Pharma · NCT07129759
TargetBeta
“Ghrelin receptor agonist”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07754045Obesity | 2 | Not yet recruiting | Lumos Pharma | Feb 15, 2028 | 202 |
| NCT07129759Dwarfism, Pituitary | 3 | Not yet recruiting | Lumos Pharma | Feb 2030 | 150 |
| NCT06948214Dwarfism, Pituitary · United States, Argentina, Australia and more | 3 | Recruiting | Lumos Pharma | Dec 2027 | 150 |
| NCT05796440Dwarfism, Pituitary · United States, Australia | 2 | By invitation | Lumos Pharma | Mar 2028 | 60 |
| NCT05250063Dwarfism, Pituitary · United States, Poland | 2 | Completed | Lumos Pharma | Jan 22, 2025 | 15 |
| NCT04806854Dwarfism, Pituitary · Chile | 2 | Active, not recruiting | Lumos Pharma | Apr 2030 | 24 |
| NCT04614337Dwarfism, Pituitary · United States, Australia, Israel and more | 2 | Completed | Lumos Pharma | Sep 4, 2024 | 104 |
| NCT00128115Hip Fractures · Germany, Norway, Spain and more | 2 | Terminated | Merck | Aug 2007 | 83 |
| NCT00074529Alzheimer Disease | 2 | Completed | Merck | Jan 2006 | 512 |
How it is read
Names in the registry
- “LUM-201”, 7 entries
- “MK0677”, 2 entries
Conditions, from the studies’ own filings
- Dwarfism, Pituitary, 6 studies
- Obesity, 1 study
- Hip Fractures, 1 study
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.